NR3C2 and primary aldosteronism: The second generation of steroidal MRAs, such as eplerenone (FDA pregnancy category B) (Craft, 2004), may be more specific to the mineralocorticoid receptor (MR), reducing off-target effects (Agarwal et al., 2021) and appears to be a safe and effective alternative in managing primary aldosteronism during pregnancy (Riester and Reincke, 2015).